63 MEDICAMENTOS EN ESPAÑA Fármacos relacionados registrados en España Irinotecán Fármaco Irinotecan Hospira EFG Medicamento® Laboratorio Año Pfizer 2004 Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica Enhertu® (trastuzumab deruxtecán). 2021. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1201508001/ FT_1201508001.pdf. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica Trodelvy® (sacituzumab govitecán). 2021. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1211592001/FT_1211592001.pdf. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Informe de posicionamiento terapéutico de trastuzumab deruxtecán (Enhertu®). 2022. Disponible en: https://www.aemps.gob.es/informa/ informes-de-posicionamiento-terapeutico/informe-de-posicionamiento-terapeutico-de-trastuzumab-deruxtecan-enhertu-en-el-tratamiento-de-pacientes-adultos-con-cancer-de-mama-her-2-positivo-localmente-avanzado-o-metastasico/. Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives. Front Oncol. 2021; 11:769280. DOI: 10.3389/fonc.2021.769280. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021; 384(16): 1529-41. DOI: 10.1056/NEJMoa2028485. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015; 21(7): 1688-98. DOI: 10.1158/1078-0432.CCR-14-0432. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017; 389(10075): 1195-205. DOI: 10.1016/S0140-6736(16)32616-2. Erratum in: Lancet. 2019; 393(10176): 1100. Cortés J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396(10265): 1817-28. DOI: 10.1016/S0140-6736(20)32531-9. Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022; 386(12): 1143-54. DOI: 10.1056/NEJMoa2115022. European Medicines Agency (EMA). Enhertu®. European Public Assessment Report (EPAR). 2021. Disponible en: https://www.ema.europa. eu/en/documents/assessment-report/enhertu-epar-public-assessment-report_en.pdf. European Medicines Agency (EMA). Trodelvy®. European Public Assessment Report (EPAR). 2021. Disponible en: https://www.ema.europa. eu/en/documents/assessment-report/trodelvy-epar-public-assessment-report_en.pdf. Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021; 32(8): 994-1004. DOI: 10.1016/j.annonc.2021.05.801. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2(4): 361-70. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020; 382(7):610-21. DOI: 10.1056/NEJMoa1914510. Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW et al. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). Eur J Cancer. 2021; 148: 28796. DOI: 10.1016/j.ejca.2021.01.053. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(1): 44-59. DOI: 10.1016/S1470-2045(19)30689-8. Sociedad Española de Oncología Médica (SEOM). Las cifras del cáncer en España. 2023. Disponible en: https://seom.org/prensa/el-canceren-cifras. Wang ZY, Yin L. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer. Mol Cell Endocrinol. 2015;418 Pt 3: 193-206. DOI: 10.1016/j.mce.2015.04.017. Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020; 22(1): 61. DOI: 10.1186/s13058-020-01296-5. Bibliografía Trastuzumab deruxtecán y Sacituzumab govitecán en cáncer de mama
RkJQdWJsaXNoZXIy MTEwMTU=